$85.80
1.11% day before yesterday
Nasdaq, May 30, 10:12 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$85.80
+14.42 20.20% 1M
+6.49 8.18% 6M
+8.03 10.33% YTD
-32.60 27.53% 1Y
+13.53 18.72% 3Y
-8.88 9.37% 5Y
+67.71 374.36% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.94 1.11%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $33.64b
Enterprise Value $33.44b
P/E (TTM) P/E ratio 66.00
EV/FCF (TTM) EV/FCF 58.14
EV/Sales (TTM) EV/Sales 8.06
P/S ratio (TTM) P/S ratio 8.11
P/B ratio (TTM) P/B ratio 14.84
Revenue growth (TTM) Revenue growth 9.11%
Revenue (TTM) Revenue $4.15b
EBIT (operating result TTM) EBIT $632.60m
Free Cash Flow (TTM) Free Cash Flow $575.20m
Cash position $2.70b
EPS (TTM) EPS $1.30
P/E forward 43.94
P/S forward 7.29
EV/Sales forward 7.25
Short interest 3.69%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a DexCom, Inc. forecast:

24x Buy
83%
5x Hold
17%

Analyst Opinions

29 Analysts have issued a DexCom, Inc. forecast:

Buy
83%
Hold
17%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,148 4,148
9% 9%
100%
- Direct Costs 1,629 1,629
17% 17%
39%
2,519 2,519
5% 5%
61%
- Selling and Administrative Expenses 1,277 1,277
6% 6%
31%
- Research and Development Expense 556 556
5% 5%
13%
858 858
1% 1%
21%
- Depreciation and Amortization 225 225
14% 14%
5%
EBIT (Operating Income) EBIT 633 633
3% 3%
15%
Net Profit 535 535
16% 16%
13%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Positive
The Motley Fool
5 days ago
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
Neutral
Business Wire
19 days ago
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO.
Neutral
Seeking Alpha
22 days ago
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the...
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 10,250
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today